The role of dolutegravir in the management of HIV infection

Infection and Drug Resistance

Volumn 8, Issue , 2015, Pages 19-29

  Miller, Misty M ^a   Liedtke, Michelle D ^a   Lockhart, Staci M ^b   Chris Rathbun, R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b ABBVIE INC   (United States)

Author keywords

Antiretroviral; Integrase inhibitor; Tivicay ; Treatment experienced studies; Treatment na ve studies

Indexed keywords

ABACAVIR; CARBAMAZEPINE; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; CYTOCHROME P450; DOFETILIDE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GLUCURONOSYLTRANSFERASE 1A1; INTEGRASE INHIBITOR; LAMIVUDINE; METFORMIN; NEVIRAPINE; ORGANIC CATION TRANSPORTER 2; PHENYTOIN; PYRIDONE DERIVATIVE; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TIPRANAVIR; UNINDEXED DRUG;

AREA UNDER THE CURVE; CEREBROSPINAL FLUID; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME SUBSTRATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84923206222     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S58706     Document Type: Review

References (59)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated May 1, 2014. Accessed October 8, 2014.
2. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.
3. Gilead Sciences. Study to evaluate the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in HIV-1 positive, antiretroviral treatment-naïve adults. Available from: http://clinicaltrials.gov/ct2/show/NCT01797445. NLM Identifier: NCT01797445. Accessed January 5, 2015.
4. Gilead Sciences. Phase 3 open-label study to evaluate switching from optimized stable antiretroviral regimens containing darunavir to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single tablet regimen plus darunavir in treatment experienced HIV-1 positive adults. Available from: http://clinicaltrials.gov/ct2/show/NCT01968551. NLM Identifier: NCT01968551. Accessed January 5, 2015.
5. Gilead Sciences. Open-label study to evaluate switching from a TDF-containing combination regimen to a TAF-containing combination single table regimen in virologically-suppressed, HIV-1 positive subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT01815736. NLM Identifier: NCT01815736. Accessed January 5, 2015.
6. Gilead Sciences. Switch study to evaluate F/TAF in HIV-1 positive participants who are virologically suppressed on regimens containing TDF/FTC. Available from: http://clinicaltrials.gov/ct2/show/NCT02121795. NLM Identifier: NCT02121795. Accessed January 5, 2015.
7. Viiv Healthcare. Dose ranging study of GSK1265744 plus nucleoside reverse transcriptase inhibitors for induction of Human Immunodeficiency Virus-1 virologic suppression followed by virologic suppression maintenance by GSK1265744 plus rilpivirine. Available from: http://clinicaltrials.gov/ct2/show/NCT01641809. NLM Identifier: NCT01641809. Accessed January 5, 2015.
8. Viiv Healthcare. A phase 2b study to evaluate a long-acting intramuscular regimen for maintenance of virologic suppression (following induction with an oral regimen of GK1265744 and abacavir/lamivudine) in Human Immunodeficiency Virus Type 1 infected, antiretroviral therapy-naïve adult subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT02120352. NLM Identifier: NCT02120352. Accessed January 5, 2015.
9. Andrews CD, Spreen WR, Mohri, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343:1151–1154.
10. Johns BA, Kawasuji T, Weatherhead JG, et al. Carbamoyl pyridine HIV-1 integrase inhibitors 3: a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013;56:5901–5916. doi:10.1021/jm400645w.
11. European Medicines Agency. Product information for Tivicay, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002753/WC500160680.pdf. Accessed November 6, 2014.
12. Hare S, Smith SJ, Métifiot M, et al. Structural and functional analysis of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80:565–572. doi:10.1124/mol.111.073189.
13. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627–1629. doi:10.1128/AAC.05739-11.
14. Tivicay (dolutegravir) tablet [product information]. Research Triangle Park, NC: GlaxoSmithKline; 2014.
15. Letendre SL, Mills AM, Tashima KT, et al. ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, ART-naïve subjects. Clin Infect Dis. 2014;59:1032–1037. doi:10.1093/cid/ciu477.
16. Greener BN, Patterson KB, Prince HM, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64:39–44. doi:10.1097/QAI.0b013e31829ed7a4.
17. Adams JL, Patterson KB, Prince HM, et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther. 2013;18:1005–1013. doi:10.3851/IMP2665.
18. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–361. doi:10.1124/dmd.112.048918.
19. Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536–3546. doi:10.1128/AAC.00292-13.
20. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737–1745. doi:10.1097/QAD.0b013e32834a1dd9.
21. Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15:9–16. doi:10.2217/pgs.13.190.
22. Song IH, Borland J, Savina PM, et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev. 2013;2:342–348. doi:10.1002/cpdd.55.
23. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate dolutegravir’s effect on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013;75:990–996. doi:10.1111/j.1365-2125.2012.0440.x.
24. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr. 2010;55:365–367. doi:10.1097/QAI.0b013e3181e67909.
25. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103–108. doi:10.1111/j.1365-2125.2011.03947.x.
26. Song I, Min SS, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol. 2011;51:237–242. doi:10.1177/0091270010371113.
27. Song I, Borland, J, Lou Y, et al. Effects of the enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572) [abstract O-02]. Paper presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13–15, 2011; Miami, FL.
28. Song I, Borland J, Chen S, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects [abstract A1-1727]. Paper presented at: 51st Annual Interscience Conference on Antimicrobial Agent and Chemotherapy; September 17–20, 2011; Chicago, IL.
29. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55:3517–3521. doi:10.1128/AAC.00073-11.
30. Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2014;57(11):5472–5477. doi:10.1128/AAC.01235-13.
31. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among health subjects. J Acquir Immune Defic Syndr. 2013;62:21–27. doi:10.1097/QAI.0b013e318276cda9.
32. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66:1567–1572. doi:10.1093/jac/dkr139.
33. Song I, Borland J, Arya N, Wynne B, Piscitelli S. The effect of calcium and iron supplements on the pharmacokinetics of dolutegravir in healthy subjects. Paper presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19–21, 2014; Washington, DC. Abstract P_13.
34. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel Integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204:1811–1815. doi:10.1093/infdis/jir636.
35. Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;3:297–301. doi:10.1097/QAI.0b013e31826bfd02.
36. DeAnda F, Hightower KE, Nolte RT, et al. Dolutegravir interactions with HIV-1 Integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One. 2013;8:e77448. doi:10.1371/journal.pone.0077448.
37. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813–821. doi:10.1128/AAC.01209-10.
38. van Lunzen J, Maggiolo F, Arribas JR, et al. Once-daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–118. doi:10.1016/S1473-3099(11)70290-0.
39. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–743. doi:10.1016/S0140-6736(12)61853-4.
40. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Eng J Med. 2013;369:1807–1818. doi:10.1056/NEJMoa1215541.
41. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383;2222–2231. doi:10.1016/S0140-6736(14)60084-2.
42. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–708. doi:10.1016/S0140-6736(13)61221-0.
43. Eron JJ, Bonaventua C, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:740–748. doi:10.1093/infdis/jis750.
44. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase 3 VIKING-3 Study. J Infect Dis. 2014;210:354–362. doi: 10.1093/infdis/jiu051.
45. Malet I, Gimferrer Arriaga L, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69:2118–2122. doi:10.1093/jac/dku095.
46. Hurt CB, Sebastian J, Hick CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis. 2014;58:423–431. doi:10.1093/cid/cit697.
47. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from randomized, double-blind, non-inferiority trial. Lancet. 2013;13:927–935.
48. Walmsley S, Berenguer J, Khuong-Josses M, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). Paper presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3–6, 2014; Boston, MA.
49. Pappa K, Baumgarten A, Felizarta F, et al. Doltegravir + abacavir/lamivudine once dialy superior to tenofovir/emtricitabine/efavirenz in treatment naïve HIV subjects: 144-week results from SINGLE (INH114467). Presented at: 54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5–9, 2014; Washington DC. Abstract H-647a.
50. Viiv Healthcare. A study to determine safety and efficacy of dolutegravir/abacavir/lamivudine in Human Immunodeficiency Virus-1 infected antiretroviral therapy naïve women. Available from: http://clinicaltrials.gov/ct2/show/NCT01910402. NLM Identifier: NCT01910402. Accessed January 5, 2015.
51. Nichols G, Lazzarin A, Maggiolo F, et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1-infected subjects with raltegraivr (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 subjects enrolled (abstract TULBPE19). Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30–July 3, 2013; Kuala Lumpur, Malaysia.
52. Vavro CL, Huang J, Avatapally C, Min S, and Ait-Khaled M. Durable efficacy and limited integrase resistance evolution in subjects receiving dolutegravir after failing prior integrase inhibititor (INI) regimens: week 48 results from VIKING-3 (abstract O_10). Presented at: 12th European Meeting on HIV and Hepatitis – Treatment Strategies and Antiviral Drug Resistance; March 26–28, 2014; Barcelona, Spain.
53. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokintetics, and efficacy of dolutegravir in treatment experienced HIV positive children. Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3–6, 2014; Boston, MA.
54. Viani RM, Alvero C, Fenton T, et al. Safety and efficacy of dolutegravir in HIV treatment-experienced adolescents: 48-week results. Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3–6, 2014; Boston, MA.
55. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life in HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125.
56. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484–488.
57. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. J Acquir Immuni Defic Syndr. 2004;36(3):808–816.
58. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15):1951–1960.
59. Murray M, Goodwin B, Hagins D, et al. Measuring patient views of HIV treatments: comparing dolutegravir with darunavir/r in the FLAMINGO study. Presented at: 20th International AIDS Conference; July 20–25, 2014; Melbourne, Australia.